#' Loebel et al 2013 Example Dataset
#'
#' This is a digitization of the Loebel et al 2013 patient-level change data, extracted from  \href{https://www.medrxiv.org/content/10.1101/2024.04.23.24306211v1}{Siegel et al, 2024}.
#'
#' @docType data
#' @name loebel_data
#' @usage data(loebel_data)
#' @format A dataframe with 361 rows (each a distinct patient) and 2 columns:
#' \itemize{
#'  \item \strong{arm}: Arm of the study: placebo, lurasidone 80mg, lurasidone 160mg, or quetiapine.
#'  \item \strong{PANSSchg}: Change from Baseline on the PANSS.
#'  }
#'  @section Source:
#'  This is approximately the data presented in Figure 3A of \href{http://www.medrxiv.org/content/10.1101/2024.04.23.24306211v1.full-text}{Siegel, J. S., Zhong, J., Tomioka, S., Ogirala, A., Faraone, S. V., Szabo, S. T., ... & Hopkins, S. C. (2024). Estimating heterogeneity of treatment effect in psychiatric clinical trials. medRxiv}, originally reported in Source of the data is \href{http://pubmed.ncbi.nlm.nih.gov/23415311/}{Loebel, A., Cucchiaro, J., Sarma, K., Xu, L., Hsu, C., Kalali, A. H., Pikalov, A., & Potkin, S. G. (2013). Efficacy and safety of lurasidone 80mg/day and 160mg/day in the treatment of schizophrenia: A randomized, double-blind, placebo- and active-controlled trial. Schizophrenia Research, 145(1), 101â€“109. doi:10.1016/j.schres.2013.01.009}.
NULL
